Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel

Author(s): Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, Singer SR, Mircus G, Brooks N, Smaja M, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis SJournal: SSRN May 2021
Israel recently initiated a rapid nationwide COVID-19 vaccination campaign to immunize persons ≥16 years of age and used exclusively Pfizer–BioNTech…

Decreased Infectivity Following BNT162b2 Vaccination

Author(s): Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, Lustig Y, Cohen C, Doolman R, Ziv A, Novikov I, Rubin C, Gimpelevich I, Huppert A, Rahav G, Afek A, Kreiss YJournal: SSRN April 2021
BNT162b2 was shown to be 92% effective in preventing COVID-19. Prioritizing vaccine rollout, and achievement of herd immunity depend on…

Long-term persistence of neutralizing memory B cells in SARS-CoV-2

Author(s): Rowena Bull, Arunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou, Chaturaka Rodrigo, Elizabeth Keoshkerian, Hui Li, Nicholas Brasher, Daniel Christ, Romain Rouet, Deborah Burnett, Branka Grubor-Bauk, William Rawlinson, Stuart Turville, Anupriya Aggarwal, Fabienne Brilot, Michael Mina, Jeffrey Post, Bernard Hudson, Nicky Gilroy, Dominic Dwyer, Sarah Sasson, Fiona Tea, Deepti Pilli, Nicodemus Tedla, Andrew Lloyd, Marianne MartinelloJournal: SSRN October 2020
Considerable concerns relating to the duration of protective immunity against SARS-CoV-2 have been raised, with evidence of antibody titres declining…

COVID-19 Futures: A Framework for Exploring Medium and Long-Term Impacts

Author(s): Juliet Bedford, Erik Berglof, Caroline Buckee, Jeremy Farrar, Bryan Grenfell, Edward C. Holmes, C. Jessica E. Metcalf, Devi Sridhar, Beth ThompsonJournal: SSRN September 2020
Considering the possible trajectories of the COVID-19 pandemic is important to inform both short- and long-term responses and to prepare…